There are 84 funds or institutions reporting positions in aTyr Pharma. This is an increase of 8 owner(s) or 10.53% in the last quarter. Average portfolio weight of all funds dedicated to ATYR is 0 ...

Today's pharmaceutical market is facing the challenges of inflation, government-imposed drug price caps and waning demand for ...

Atyr PHARMA (NASDAQ:ATYR – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Tuesday,Benzinga reports.

However, when multiple insiders purchase stock, like in aTyr Pharma, Inc.'s (NASDAQ:ATYR) instance, it's good news for shareholders. Although we don't think shareholders should simply follow ...

Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on aTyr Pharma (ATYR – Research Report). The associated price target remains the same with $22.00. Pick the best stocks and ...

Following the event, a replay of the presentation will be available on the aTyr website for at least 30 days. For more information, contact [email protected]. About aTyr aTyr is a ...

aTyr Pharma (ATYR) announced that the Company will present two posters related to its tRNA synthetase candidate ATYR0101 at the Keystone Symposia on Fibrosis: Inflammation, Drivers, and ...

aTyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company, is garnering attention from investors and analysts alike as it advances its lead candidate, efzofitimod, through late-stage ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...